|
T.RVX
|
Perhaps the actual presentation contained new data, but the abstract below...
|
|
T.RVX
|
If my notes serve me correctly, RVX presents an oral presentation in the next...
|
|
T.RVX
|
Consistent with what GV said, I emailed Sara asking when the trial approval...
|
|
T.RVX
|
Tundup, There are many steps in getting the trial launched. First is the...
|
|
T.RVX
|
JK, Thanks for sharing. Since RVX-208 is an HDL-raising therapy, it was not...
|
|
T.RVX
|
I don't know if any ESPR consolidation occured. They were bougth by...
|
|
T.RVX
|
Yeah, ETC-1002 looks to have a lot of promise. Lots of success in numerous...
|
|
T.RVX
|
It very effectively communicates the effectiveness of RVX-208 in the proper...
|
|
T.RVX
|
Here is the ACC abstract, slated for the afternoon of March 16th. http://www...
|
|
T.RVX
|
Momentum for RVX seems to be building as we head into the end of Q1 aka March...
|
|
T.RVX
|
I'm not sure abou the half-life of the torcetrapib or dalcetrapib, but...
|
|
T.RVX
|
Torcetrapib had adverse effects of increased blood pressure and circulating...
|
|
T.RVX
|
Sir Holler, SUSTAIN and ASSURE included patients taking 5, 10 or 20 mg/day...
|
|
T.RVX
|
Tundup, RVX-208 is an inhibitor of the BET (bromodomain and extra...
|
|
T.RVX
|
I took a quick glance at the article. "A total of 2,142 (24.5%) of the 8...
|
|
T.RVX
|
SanFran, It seems very unlikely that there will be four separate trials...
|
|
T.RVX
|
JK. That is very interesting on 2 levels. First off, I didn't realize...
|
|
T.RVX
|
Fouremm, Sorry for the belated response. The primary endpoint for the...
|
|
T.RVX
|
And later in March, Dr. Wong gives an oral presentation at the European...
|
|
T.RVX
|
It's still a month away, but looks like Resverlogix will be presenting in...
|